The rapid growth of social prescribing in England: analyses of primary care medical records using data from the Clinical Practice Research Datalink (CPRD)

Dr Feifei Bu[1†*], Dr Alexandra Burton[1,2 †], Dr Naomi Launders[3], Dr Amy E. Taylor[4], Alvin Richards-Belle[3], Dr Stephanie Tierney[5], Prof David Osborn[3,6], Prof Daisy Fancourt[1]

[1] Department of Behavioural Science and Health, University College London
[2] Wolfson Institute for Population Health, Centre for Psychiatry and Mental Health, Queen Mary University of London
[3] Division of Psychiatry, University College London
[4] Division of Surgery and Interventional Science, University College London
[5] Nuffield Department of Primary Care Health Sciences, University of Oxford
[6] North London NHS Foundation Trust

[†] Joint first author
*Corresponding author: Dr Feifei Bu, Department of Behavioural Science and Health, University College London, 1-19 Torrington Place, London, WC1E 7HB, Email: f.bu@ucl.ac.uk

Word count: 3595
Number of tables: 2
Number of figures: 5

The rapid growth of social prescribing in England: analyses of primary care medical records using data from the Clinical Practice Research Datalink (CPRD)

Abstract

Objective: To understand the growth of social prescribing in primary care and the scale and equity of the roll-out

Design: Observation study

Setting: England

Participants: 1.2 million patients from 1,736 practices in the Clinical Practice Research Datalink from 2009 to the end of 2023

Main outcome measures: Social prescribing discussions and referrals

Results: Since the start of the national roll-out of social prescribing in 2019, there has been a clear linear increase in social prescribing being coded within primary care records. As of the end of 2023, an estimated 9.5m GP consultations in England have involved social prescribing codes, and 5.6m consultations have specifically led to social prescribing referrals. In 2023, social prescribing referrals exceeded NHS targets by 26.7 to 51.1%, reflecting rapid adoption. In 2023, females constituted 60.4% of social prescribing patients and ethnic minority groups represented 21.7%. Representation from patients living in more deprived areas increased from 21.7% prior to the national roll-out to 42% in 2023. Service refusal declined from 22.2% to 10.6% between 2019 and 2023. Females and less deprived patients were less likely to decline referrals, risking reinforcing existing group disparities, while younger age groups (<30) exhibited high referral uptake despite their lower level of referrals.

Conclusions: Social prescribing has expanded rapidly in England, exceeding initial NHS targets and demonstrating the importance of the service. Progress is being made in reaching certain target groups such as more deprived communities. However, there are still disparities in accessibility and engagement, calling for targeted strategies and diverse referral pathways to fulfil social prescribing's full potential.

Keywords: social prescribing, non-clinical intervention, primary care, equality, equity

Introduction

Social prescribing is an innovative approach to healthcare that connects patients to non-clinical services in their local community to support their health and wellbeing.[1] These non-clinical services include a wide range of activities such as exercise, volunteering, arts and culture, counselling, befriending, training courses, housing support, benefits and employment advice.[2] Social prescribing can be implemented through various models, tailored to the specific needs of communities and healthcare systems.[3] In England, the predominant model is the general practitioner (GP)-link worker model where a healthcare professional in primary care (usually a GP) refers patients to a link worker (or other similar professionals) who then works with the patient to develop a personalised care plan that connects them to community support and interventions.[2] The importance of social prescribing lies in its potential to address the social, emotional, and practical needs of patients that are often interrelated to medical needs but are not covered

by clinical treatments, and which form an estimated 20% of GP consultations.[4] As such, social prescribing provides a more holistic approach to patient care that complements existing clinical interventions, bridging critical service gaps. It also has the potential to alleviate pressure on primary care by diverting these non-clinical consultations to community services.

In 2019, social prescribing became an established part of the healthcare system in England with the publication of the NHS Long Term Plan.[5] This led to a roll-out of link workers across England with funding announced for 1,000 link workers in 2019. In 2022, it became a formal mandate for every Primary Care Network to provide social prescribing as part of its service,[6] and in 2023, the NHS Long Term Workforce Plan included a rising commitment to fund 9,000 link workers by 2036/2037.[7] However, there has been little research thus far on how successfully social prescribing has been implemented in England over time. Analysis of the roll-out of link workers within Primary Care Networks has reported that the NHS did not meet its target of employing 1,000 link workers by 2020/21 and found inequalities geographically, with areas that recorded the greatest need for additional support recording the lowest levels of link worker employment across England.[8] However, analysis of data from a large cloud-based social prescribing referral-management platform, from over 160,000 patients who had received social prescribing referrals, suggested the number of referrals in more deprived areas may be higher than in less deprived areas.[2] This finding is echoed in self-reports of social prescribing referrals from older adults in national cohort data, which again found that those receiving benefits and with lower wealth were more likely to report having received a referral.[9] Nonetheless, we currently lack any large-scale analyses of how many people have been offered social prescribing through the GP-link worker model and how equitable these referrals have been over time. NHS England set the target of referring over 900,000 people to social prescribing by 2023/2024, but whether this has been met is undetermined.[5] Moreover, there have been concerns that social prescribing could exacerbate existing inequalities if it is not accessed equitably by individuals from disadvantaged backgrounds.[10,11]

Drawing data from national primary care records, the aims of the present study were threefold: (1) to depict how social prescribing activity in primary care has developed over the past 15 years in England, estimating the number of referrals to date compared to national targets, estimating social prescribing prevalence year on year, and tracking trajectories of growth; (2) to explore the sociodemographic profiles of adult patients referred to social prescribing and their trends over time; (3) to map uptake vs refusal of social prescribing and identify patterns and trends in predictors of social prescribing service refusal. These aims are critical to understanding the growth and future potential of social prescribing at a key moment in future planning for the NHS in England.

Methods

Data

Data were from the Clinical Practice Research Datalink (CPRD); a research data service that collects anonymised patient data routinely from a network of over 2000 GP practices across the UK. CPRD contains rich data on demographics, diagnoses and symptoms, prescriptions, tests and referrals from over 60 million patients over more than 35 years since 1989, including over 18 million currently registered patients. This study focused on England using data from CPRD Aurum which covers over 20% of general practices

and has been shown to be representative of the English population in terms of geographic area, deprivation, urbanicity, age and gender.[12,13]

To map rates and trends in social prescribing activity (research aim 1), data were analysed aggregately using all data with a medical code related to social prescribing. Although our primary analyses focused on social prescribing, as a point of comparison, we additionally ran analyses using medical codes relating to other common non-clinical interventions that are similar or closely related to social prescribing, as detailed below, to understand how changes in social prescribing compare to changes in these other interventions over time.

To map sociodemographic profiles of people referred to social prescribing (research aim 2) and patterns and predictors of service refusal (research aim 3), we used patient level data. To be included in these analyses, patients had to be aged 18 or over who were permanently registered and with a minimum follow-up of 12 months for data quality control purposes.

Data extraction was carried out in November 2024, restricted to the period of 2009-2023, starting from 10 years before the publication of the NHS Long Term Plan and excluding incomplete data in 2024. In total, this provided an analytical sample of around 1.2 million patients from 1,736 practices for the analysis for research aim 1, 0.9 million patients for research aim 2, and 0.7 million for research aim 3.

Measures

Consultations related to social prescribing were identified using the code lists (read codes or SNOMED) in table 1, which included any discussion related to social prescribing. For research aim 1, we additionally considered medical codes related to other non-clinical interventions, including community navigator, health coach, health trainer, and health and wellbeing worker/coach (Table 1). For research aims 2 and 3, we focused exclusively on social prescribing codes.

For research aim 2, sociodemographic covariates included age groups derived from year and year of birth (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+), sex (male, female), ethnicity (white, ethnic minority), area deprivation in deciles measured by the index of multiple deprivation based on patient postcode, area urbanicity (rural, urban) based on the Rural Urban Classification from the 2011 census and region of primary care practices (North East, North West, Yorkshire and the Humber, East Midlands, West Midlands, East of England, London, South East, South West).

For research aim 3, we were interested in medical codes indicating whether social prescribing referrals were declined or accepted. Service refusal was defined as 'social prescribing declined' in contrast to 'referral to social prescribing services (from other agency)/seen by social prescribing link worker'. If refusal and referral codes cooccurred, it was coded as refusal. We considered other codes if they were used in conjunction with social prescribing codes in the same consultation (e.g. 'social prescribing offered' + 'referral to community navigator' coded as referral). See Table 1 for details. For these analyses, we excluded any codes without any clear indication of uptake (e.g. 'social prescribing offered', 'signposting to social prescribing service', 'social prescribing for mental health' ~23-35%). Service refusal/uptake was measured at patient level. If a patient had multiple consultations in a given year, the most recent consultation was used.

Table 1 Social prescribing data extraction code list in CPRD Aurum

Group	SNOMED term	Read code terms
Social prescribing	Referral to social prescribing service [a] Social prescribing offered Seen by social prescribing link worker [a] Signposting to social prescribing service Review of social prescribing plan Social prescribing declined [r] Social prescribing case closed Social prescribing plan completed Social prescribing for mental health Not suitable for social prescribing Referral to social prescribing service from other agency [a]	Referral to social prescribing service [a] Social prescribing offered Social prescribing declined [r] Social prescribing for mental health
Community navigator	Seen by community navigator [a] Referral to community navigator [a]	Seen by community navigator [a] Referral to community navigator [a]
Health coach	Health coach initiated encounter [a] Referred for health coaching [a] Seen by health coach [a] Patient initiated health coach encounter [a] Referral for health coaching [a]	Health coach initiated encounter [a] Referred for health coaching [a] Patient initiated health coach encounter [a] Seen by health coach [a]
Health trainer	Referral to health trainer declined [r] Referral to health trainer [a] Seen by health trainer [a] Signposting to health trainer	Referral to health trainer declined [r] Referral to health trainer [a] Seen by health trainer [a] Signposting to health trainer
Health & wellbeing worker/coach	Seen by health and wellbeing coach [a] Signposting to health and wellbeing worker	

Notes: r: refusal of social prescribing; a: acceptance/uptake of social prescribing

Statistical Analysis

For research aim 1, data were first analysed descriptively showing the number of GP consultations related to social prescribing and other non-clinical interventions by year between 2009 and 2023. We then fitted a series of growth curve models to examine the average growth trajectories of social prescribing and other similar non-clinical interventions, as well as their variations across GP practices. The time variable, year, was initially used as a discrete variable represented by dummy variables, allowing the shape of trajectories to be freely estimated. Subsequently, linear growth models were applied where appropriate to balance model parsimony and mitigate overfitting risks. Based on estimates of an average practice, we calculated national estimates by multiplying results by the total number of GP practices in England in each year.[14] Growth curve analyses were restricted to 2017-2023 due to small sample sizes in earlier years.

For research aim 2, we carried out descriptive analyses showing the sociodemographic profiles of patients with a social prescribing code by year in the period of 2017-2023.

For research aim 3, we used multilevel logistic regression models to examine how sociodemographic factors were associated with service refusal, accounting for the nested data structure (patients within practices), which were stratified by year. These analyses were restricted to periods of 2019-2023 due to small sample sizes in earlier years.

Missing data were minimal for most sociodemographic covariates except for area deprivation and urbanicity (~20%) that were obtained via postcode linkage. We used complete case analysis for the main analyses, but sensitivity analyses, using multiple imputation with chained equations, were carried out for research aim 3 (MI=20). All analyses were conducted in Stata V18.

Results

Research aim1: Trends in social prescribing over time

Social prescribing was implemented sparingly in England before 2019. It began to increase rapidly and steadily after the national roll-out in 2019, even during the COVID-19 pandemic (Figure 1a). This marked a clear change from prior to 2019, when there had only been small increases in similar non-clinical interventions, although it is notable that community navigator and health coaching had begun rising from 2015 (Figure 1b). Other than a slight decline in health trainers, these other non-clinical services have continued to grow, suggesting that social prescribing did not simply replace existing non-clinical services. In percentage distribution, though, social prescribing represented as the largest share of these activities from 2020 onwards, although its percentage growth has stalled even though absolute numbers of consultations continue to rise (Figure 1c).

Growth trajectories based on analyses from 1,736 GP practices suggested the rise in social prescribing was approximately linear since 2019, increasing by roughly 126 consultations or 61 patients per GP practice each year (Figure 2a and Table 2). In 2023 alone, there were an estimated 544 consultations (95% CI: 508-579) and 278 patients (95% CI: 254-302) related to social prescribing per practice. If extrapolated to represent all GP practices in England, we estimated that roughly 1.6-1.9 million patients had social prescribing codes, based on the total number of 6,311 GP practices in England in 2023.[15] If restricting to patients with referral codes only, the estimates were 1.1-1.4 million. To extrapolate across years, this equates to an estimated 8.8-10 million consultations including any discussions of social prescribing from 2019 to the end of 2023, 5.2-5.9 million of which had social prescribing codes specifically indicating that referrals took place (Table 2).

Growth trajectories for comparison activities are shown in Figure 2b-2e, which were largely consistent with the descriptive analysis and were much smaller in numbers compared to social prescribing.

Table 2 Sample counts and estimates from linear growth curve model on social prescribing 2019-2023

year		N consultations in CPRD	Predicted N consultations in England †	N patients in CPRD	Predicted N patients in England †	N practice in CPRD	N practice in England ‡
All:	2019	46311	267461 [143723, 391199]	34962	235514 [152005, 319023]	1666	6836
	2020	315333	1093958 [995646, 1192271]	195277	630711 [564462, 696961]	1700	6616
	2021	460471	1901655 [1780867, 2022443]	246137	1018805 [937608, 1100001]	1683	6522
	2022	737616	2683114 [2513911, 2852318]	389527	1394150 [1280459, 1507841]	1668	6422
	2023	874612	3433345 [3208050, 3658639]	438625	1754262 [1602863, 1905661]	1620	6311
	Total	2434343	9379533 [8781650, 9977416]	--	--	--	--
Referral:	2019	22668	74048 [8349, 139747]	18424	126967 [69560, 184374]	1666	6836
	2020	155929	611744 [555131, 668357]	118512	420318 [373604, 467031]	1700	6616
	2021	273466	1135458 [1058034, 1212883]	182197	707557 [648063, 767051]	1683	6522
	2022	441452	1642291 [1531899, 1752683]	278257	985424 [901545, 1069303]	1668	6422
	2023	549190	2129087 [1982855, 2275318]	309092	1252117 [1140641, 1363593]	1620	6311
	Total	1442705	5541636 [5160997, 5922276]	--	--	--	--

Notes: † Estimates based on linear growth curve model (2019-2023) with random intercept and slope; ‡ Number of practices in December each year obtained from NHS digital, general practice workforce, 31 December 2024

Research aim 2: Sociodemographic patterning of social prescribing referrals over time

In total, we identified around 0.9 million adult patients with social prescribing codes between 2017 and 2023. Sample sizes varied across years and sociodemographic variables, ranging from 11260 to 720410 patients (Table S1-S4). Since 2017, females were overrepresented in social prescribing consultations, accounting for around two thirds of patients consistently (Figure 3a, Table S1). Patients from ethnic minority backgrounds accounted for around 1 in 5 consultations in 2023, showing a gradual increase since 2020 (Figure 3b, Table S1). There was a slight but steady increase in the percentage of younger adults receiving social prescribing codes since 2020 (Figure 3c, Table S3). Notably, patients from areas ranked in the top five most deprived deciles had also been increasing their access to social prescribing, accounting for only 23% of referrals in 2017 but 42% in 2023 (Figure 3d, Table S3). Only around 13% of referrals were for individuals from rural areas, which had been stable since 2020 (Figure 3e, Table S1). Substantial changes in regional profiles are observable. For example, the percentage share of patients from London, the North East, Yorkshire and Humber, and South West decreased since 2017 as increasing numbers of patients from the West Midlands and North West had been accessing the service, now accounting for 23% and 20% respectively of all social prescribing patients (Figure 3f, Table S4). However, it is important to note that caution should be taken comparing across regions as the distribution of GP practices within CPRD was not equal across geographical regions.

Research aim 3: Patterns and predictors of service refusal

In total, 0.7 million adult patents were included in the multilevel regression analyses between 2019 and 2023, with varying sample sizes and patient characteristics (Table S5). In 2019, 22.2% of patients had a record of service refusal, which declined to 10.6% in 2021 and remained stable since (Figure 4). It is of note that in 2019, most variance in service refusal for social prescribing was between practices (71.9%), which dropped to 42.2% by 2023, suggesting that practices had grown more similar to each other, and patient (instead of practice) characteristics played an increasingly important role in service refusal. Results from regression models suggested that older age groups were more likely to refuse referrals, especially since 2020 (Figure 5, Table S6). While sex was not a predictor of refusal in 2019, females consistently had 19-21% lower odds of refusal since 2020. Notably, patients of white ethnicity had higher odds of refusal than those from ethnic minority backgrounds in all years. There was no evidence that area deprivation was related to refusal in 2019, but over time, patients from less deprived areas had become less likely to refuse. For instance, patients from the least deprived areas had 34% lower odds of refusal compared to their most deprived counterparts in 2023. There was no evidence that urbanicity was associated with social prescribing refusal in any of the years, but there were some disparities across regions, including higher odds of refusal in the North East, West Midlands and North West compared to patients in London, since 2021. Results from models with multiple imputation were consistent with the main analyses (Table S7).

Discussion

Our study analysed data from a maximum of 1.2 million patients from CPRD, providing the first detailed analyses of the national roll-out of social prescribing in England. Our findings demonstrate a rapid expansion of social prescribing through GP practices since 2019. From 2019-2023, an estimated 8.8-10

million GP consultations involved discussions about social prescribing, with over 5.2-5.9 million consultations leading to a referral. In 2023 alone, an estimated 1.6-1.9 million patients discussed social prescribing with their GP and 1.1-1.4 million received a referral. These figures represent conservative estimates as they do not include other related codes (e.g. community navigators, health trainers, etc. unless used in combination with social prescribing codes) that may (or may not) be used interchangeably with social prescribing. They also do not include referrals from alternative routes, such as secondary care, voluntary and community sector organisations, statutory services, self-referral or patients who are referred but potentially not coded as such. These figures suggest social prescribing has exceeded the NHS Long Term Plan's target of 900,000 patients in 2023/2024 by 26.7-51.1%,[5] underscoring a widespread recognition and adoption of social prescribing within the primary care system.

While social prescribing aims to reduce health inequalities, concerns have been raised that it may inadvertently exacerbate inequality by disproportionately benefiting less disadvantaged populations as a result of structural inequalities.[10,11] In addition to concern about geographical inequalities in the roll-out of link workers, some pilot studies have reported lower referrals from individuals facing more socio-economic disadvantage.[8,16,17] Our analyses found that in 2023, 42% of social prescribing patients were from the top five most deprived deciles geographically. While this indicates that there is not yet equality nor equity in the complete distribution of social prescribing, it is notable that this figure is nearly double the percentage reported in 2017, and the percentage share from the most deprived areas is increasing year on year. There have also previously been concerns that individuals from ethnic minority backgrounds might be less likely to engage.[16–18] But as of 2023, 21.7% of social prescribing patients were identified as ethnic minorities, surpassing the national estimate of the percentage of individuals from ethnic minorities (19.3%) in the general population.[19] Furthermore, individuals from ethnic minority backgrounds appear more likely to take up social prescribing referrals. However, it is clear that work is still needed to ensure equity in social prescribing. For example, we found an underrepresentation of rural residents comparing to national statistics (13% vs 17%),[20] a gap persisting since 2020. This may be partially explained by the slightly overall underrepresentation of rural residents in CPRD (15% vs 17%),[13] but it may be also related to limited community resources in some rural settings. In line with previous literature,[16,17] our findings reveal a consistent overrepresentation of females among social prescribing patients throughout the study period. Further, males and people from more deprived areas appear less likely to take up referrals even if they are referred. These findings corroborate earlier findings from the Social Prescribing Observatory,[21] and highlight the importance of ensuring that existing gender- and deprivation-based disparities are not amplified through differences in service uptake by undertaking more extensive research into the accessibility and effectiveness of social prescribing for different groups. It is important to note that some of the group differences reported align with broader biases in healthcare-seeking behaviour and primary care utilisation.[22] Furthermore, our data only focus on GP referrals, and in previous analyses, individuals from more deprived groups and ethnic minority groups are found more likely to access social prescribing through non-clinical referral routes such as voluntary and community sector organisations, statutory services and self-referral.[2] So if targets are to overrepresent individuals from certain backgrounds (e.g. higher deprivation and ethnic minority groups) in social prescribing referrals given their higher health risks,[23] it will be important not only to ensure equitable referrals to social prescribing via GP practices, but also to simultaneously invest in non-GP referrals. For example, recent work using routine data covering a variety of referral pathways, suggests that young adults – who are underrepresented in primary care - are

more likely to access social prescribing via non-clinical routes.[2] Therefore, it is important to recognise and continue to research the complementary roles of different pathways to reach underrepresented populations.

The main strength of our study is its use of a national longitudinal primary care dataset (CPRD) to analyse social prescribing trends over a multiple-year period. Other strengths include the consideration of other terms related to social prescribing and robust analytical approaches accounting for nested data structure and missing data. However, several limitations should be noted. First, as our sample are restricted to patients with social prescribing codes, we cannot compare them to patients not considered for social prescribing. Nevertheless, our study does provide valuable insights into the sociodemographic profiles of social prescribing patients and their temporal trends. Second, CPRD data currently lack granular detail in social prescribing, without any information on referral reasons, prescribed interventions, uptake of these interventions, and patient outcomes. This prevents us from obtaining a comprehensive and in-depth understanding of social prescribing's reach and impact. But recent updates to coding systems, incorporating newly added social prescribing codes, present opportunities to address these gaps in future work. Third, in this study, we have considered social prescribing as well as related terms such as community navigator, health coach, health trainer, and health and wellbeing worker/coach that are captured in CPRD Aurum. While these terms are occasionally used in combination with social prescribing codes, they are predominantly recorded independently. Therefore, it is unclear whether they are used as precursors, subdomains, or standalone equivalents to social prescribing. This lack of clarity highlights the urgent need for standardised definitions and coding practice to enhance data comparability for research and policy evaluation in this rapidly evolving field. Forth, our national projections of social prescribing nationally rely on the assumption that practices in CPRD constitute a nationally representative sample. While previous studies have established CPRD's representativeness of the national population,[12,13] its representativeness at the practice level is yet to be tested, meaning that these estimates should be interpreted with caution. Additionally, for research aim 3, we categorised social prescribing codes intuitively based on whether they indicated acceptance or refusal. However, given the multiple codes available for social prescribing, it is possible that GPs may have used neutral codes (e.g. social prescribing offered) rather than acceptance/refusal specific codes, so we potentially underestimate the true samples for both acceptance and refusal. Finally, our analyses focus specifically on GP referrals, so they do not provide a complete picture of all social prescribing referrals in England, and GP referrals should not be considered the only viable pathway for social prescribing.

Our study highlights the rapid expansion and evolving demographic landscape of social prescribing through GP practices, with referrals surpassing national targets by at least 27–51% in 2023. At a time when the future of the NHS is being redesigned, these results highlight the clear appetite for social prescribing in primary care and the sizeable and growing number of patients who are being referred each year. Promisingly, there are increasing representations of ethnic minorities, younger adults, and those living in deprived areas accessing the service. However, addressing disparities in accessibility and engagement requires targeted strategies and diverse referral pathways to ensure social prescribing fulfils its promise as a tool to address social determinants of health. Overall, our findings underscore the importance of systematic and ongoing monitoring of social prescribing implementation locally and nationally.

Article information

Author contributions:

FB, DF and AB conceptualised this study. AB and AT gained data access. FB cleaned and analysed the data. FB and DF interpreted the results and wrote the manuscript. ARB, NL and DO advised on data management. All authors contributed to writing (review and editing). AB gained funding for the study. All authors approved the final manuscript.

Funding:

This work is supported by the MQ Transforming Mental Health and Rosetrees - Stoneygate Trust Fellowship (MQF22\6) awarded to AB. NL is supported by a Health Data Research UK personal fellowship. This work is affiliated to Health Data Research UK (Big Data for Complex Disease- HDR-23012), which is funded by the Medical Research Council (UKRI), the National Institute for Health Research, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council (UKRI), the Engineering and Physical Sciences Research Council (UKRI), Health and Care Research Wales, Chief Scientist Office of the Scottish Government Health and Social Care Directorates, and Health and Social Care Research and Development Division (Public Health Agency, Northern Ireland).

Ethics statements:

Ethical approval for this study was obtained from the Independent Scientific Advisory Committee of CPRD (protocol no. 24_004142).

Data availability statement:

The original data from this study are provided by Clinical Practice Research DataLink (CPRD). Data cannot be shared publicly because they are not publicly available. CPRD may provide researchers with data following completion of their approvals and ethics process: https://www.cprd.com/research-applications

Reference

1 Morse DF, Sandhu S, Mulligan K, Tierney S, Polley M, Giurca BC *et al.* Global developments in social prescribing. *BMJ Glob Health* 2022; **7**: e008524.

2 Bu F, Hayes D, Burton A, Fancourt D. Equal, equitable or exacerbating inequalities: patterns and predictors of social prescribing referrals in 160 128 UK patients. *The British Journal of Psychiatry* 2024; : 1–9.

3 Oster C, Skelton C, Leibbrandt R, Hines S, Bonevski B. Models of social prescribing to address non-medical needs in adults: a scoping review. *BMC Health Services Research 2023 23:1* 2023; **23**: 1–20.

4 Torjesen I. Social prescribing could help alleviate pressure on GPs. *BMJ* 2016; **352**: i1436.

5 NHS England. The NHS Long Term Plan. 2019www.longtermplan.nhs.uk (accessed 7 Feb2024).

6 NHS. Network Contract Directed Enhanced Service. 2022.

7 NHS England. NHS Long Term Workforce Plan. 2023https://www.england.nhs.uk/long-read/accessible-nhs-long-term-workforce-plan/#:~:text=This%20Plan%20sets%20out%20modelling,over%20the%20next%20two%20years. (accessed 18 Jul2023).

8 Wilding A, Sutton M, Agboraw E, Munford L, Wilson P. Geographic inequalities in need and provision of social prescribing link workers a retrospective study in primary care. *British Journal of General Practice* 2024; **74**: e784–e790.

9 Fancourt D, Steptoe A. Can social prescribing reach patients most in need? Patterns of (in)equalities in referrals in a representative cohort of older adults in England. *medRxiv* 2024; : 2024.03.26.24304891.

10 Moscrop A. Social prescribing is no remedy for health inequalities. *BMJ* 2023; **381**. doi:10.1136/BMJ.P715.

11 Gibson K, Pollard TM, Moffatt S. Social prescribing and classed inequality: A journey of upward health mobility? *Soc Sci Med* 2021; **280**: 114037.

12 Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J *et al.* Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol* 2019; **48**: 1740.

13 Mahadevan P, Harley M, Fordyce S, Hodgson S, Ghosh R, Myles P *et al.* Completeness and representativeness of small area socioeconomic data linked with the UK Clinical Practice Research Datalink (CPRD). *J Epidemiol Community Health* 2022; **76**: 880–886.

14 Casella G, Berger RL. *Statistical Inference*. 2nd ed. CRC Press: Boca Raton, 2024.

15 NHS England Digital. General Practice Workforce. 2023.https://digital.nhs.uk/data-and-information/publications/statistical/general-and-personal-medical-services/30-november-2023# (accessed 24 Jan2025).

16 Khan K, Tierney S. The Role of Social Prescribing in Addressing Health Inequalities. *Social Prescribing Policy, Research and Practice* 2024; : 31–45.

17 Cartwright L, Burns L, Akinyemi O, Carder-Gilbert H, Tierney S, Elston J *et al.* Who is and isn't being referred to social prescribing? London, 2022.

18 Khan K, Al-Izzi R, Montasem A, Gordon C, Brown H, Goldthorpe J. The feasibility of identifying health inequalities in social prescribing referrals and declines using primary care patient records. *NIHR Open Research 2023 3:1* 2023; **3**: 1.

19 ONS. Ethnic group, England and Wales. 2022.https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/bulletins/ethnicgroupenglandandwales/census2021 (accessed 5 Mar2025).

20 Hall S, Harriss S, Kerwin B, Fowell M. Statistical digest of rural England: 1-Population . 2024.

21 Jani A, Liyanage H, Okusi C, Sherlock J, Hoang U, McGagh D *et al*. Health inequalities and personalised care in England April 2017–March 2021. 2021.

22 Wang Y, Hunt K, Nazareth I, Freemantle N, Petersen I. Do men consult less than women? An analysis of routinely collected UK general practice data. *BMJ Open* 2013; **3**: e003320.

23 Pearce JR, Richardson EA, Mitchell RJ, Shortt NK. Environmental justice and health: the implications of the socio-spatial distribution of multiple environmental deprivation for health inequalities in the United Kingdom. *Transactions of the Institute of British Geographers* 2010; **35**: 522–539.

Figures



Figure 1. Numbers and percentages of GP consultations related to social prescribing and other non-clinical interventions by year. Notes: dashed lines in Figure 1b removing double counts if other non-clinical codes were used in with social prescribing in the same consultation



Figure 2. Average growth trajectories of numbers of consultations and patients across GP practices between 2017 and 2023 based on growth curve models with discrete time



Figure 3. Changes in sociodemographic profiles of patients with social prescribing codes between 2017 and 2023



Figure 4. Refusal percentages and intraclass correlation coefficients (ICCs) from unconditional multilevel logistic regression models by year



Figure 5. Odds ratios and their 95% confidence intervals from multilevel logistic regression models by year († large values capped at 4)